本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Akari Therapeutics PLC

0.8101
-0.0023-0.28%
成交量:1.87万
成交额:1.54万
市值:2,642.12万
市盈率:-1.49
高:0.8340
开:0.8201
低:0.8100
收:0.8124
52周最高:3.85
52周最低:0.5714
股本:3,261.47万
流通股本:562.08万
量比:0.03
换手率:0.33%
股息:- -
股息率:- -
每股收益(TTM):-0.5428
每股收益(LYR):-1.6570
净资产收益率:-112.02%
总资产收益率:-28.56%
市净率:1.03
市盈率(LYR):-0.49

数据加载中...

2024/05/16

重要事件披露

Form 8-K - Current report
2024/05/15

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

重要事件披露

Form 8-K - Current report
2024/05/01

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2024/05/01

重要事件披露

Form 8-K - Current report
2024/04/11

重要事件披露

Form 8-K - Current report
2024/04/01

重要事件披露

Form 8-K - Current report
2024/03/29

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/03/11

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2024/03/11

重要事件披露

Form 8-K - Current report
2024/03/05

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2024/03/05

重要事件披露

Form 8-K - Current report
2024/01/05

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/01/03

重要事件披露

Form 8-K - Current report
2023/10/25

SEC问询函

Form CORRESP - Correspondence
2023/10/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/10/13

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/31

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/01

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]